Industry News

Pharmaceutical Industry News

Robert F. Kennedy Jr. is starting…

April 9th, 2026|Fierce Pharma|

Robert F. Kennedy Jr. is starting a podcast. Unveiling the show on social media, the Department of Health and Human Services (HHS) secretary framed the podcast as a response to public health problems that he

A federal judge rejected the Trump…

April 8th, 2026|Fierce Pharma|

A federal judge rejected the Trump administration's bid to dismiss a group of states' lawsuit challenging Robert F. Kennedy Jr.'s restructuring of the Department of Health and Human Services.

From a negative phase 3 readout…

April 8th, 2026|Fierce Pharma|

From a negative phase 3 readout and a seemingly tightening regulatory climate to a grueling three-month review extension, Travere has defied the odds, securing Filspari a landmark FDA approval as the first treatment for the

After more than a decade in charge…

April 8th, 2026|Fierce Pharma|

After more than a decade in charge of the most influential organization representing the U.S. pharmaceutical industry, PhRMA, Steve Ubl will step down as its CEO at the end of the year.

Biogen has agreed to a settlement…

April 8th, 2026|Fierce Pharma|

Biogen has agreed to a settlement with investors who claimed the company misled them in describing how it gained a controversial FDA approval for failed Alzheimer’s treatment, Aduhelm.

With a solid year of double-digit…

April 8th, 2026|Fierce Pharma|

With a solid year of double-digit revenue growth in the books, Amgen’s longtime helmsman Robert Bradway continues to sit firmly in the upper echelons of biopharma CEO pay, though not quite at the level seen

Johnson & Johnson’s…

April 8th, 2026|Fierce Pharma|

Johnson & Johnson’s immunology drug Tremfya is looking to challenge AbbVie’s dominance in 2026, securing the top spot as the biggest TV drug ad spender in March.

U.S. Olympic gold medal-winning…

April 8th, 2026|Fierce Pharma|

U.S. Olympic gold medal-winning athlete Lindsey Vonn is once again teaming up with infectious disease biopharma Invivyd for a new campaign centering on antibody-based treatments.

The plummeting demand for…

April 7th, 2026|Fierce Pharma|

The plummeting demand for Merck’s HPV vaccine Gardasil in China has forced the New Jersey drugmaker to rework its arrangement with its partner in the country, Zhifei Biological Products.

The FDA is seeking new powers to…

April 7th, 2026|Fierce Pharma|

The FDA is seeking new powers to hold companies accountable for misleading direct-to-consumer ads, adding legislative weight to its pushback against deceptive drug advertising.

In response to a warning letter…

April 6th, 2026|Fierce Pharma|

In response to a warning letter from the FDA that accused the company of making “false or misleading” claims about its bladder cancer drug Anktiva, ImmunityBio says it’s implementing enhanced protocols.

Neurocrine Biosciences, forever a…

April 6th, 2026|Fierce Pharma|

Neurocrine Biosciences, forever a possible M&A target in the biopharma industry, is making a major acquisition itself. The purchase adds to a recent string of multibillion-dollar deals.